Annovis Bio, Inc. (ANVS) investor relations documents from the company's IR site: 3 presentations, 2 press releases; latest deck 2026-08-03. Read in-app with summaries. First-party data.
Investor Deck: Annovis Bio is developing buntanetap, an oral drug candidate for Alzheimer’s and Parkinson’s disease, currently in late-stage clinical trials toward NDA filing.
| Published | Type | Document |
|---|---|---|
| 2026-08-03 | Presentation | Investor Deck |
| 2026-05-14 | Presentation | Investor Deck |
| 2026-05-14 | Presentation | Download Now |
| 2026-03-16 | Press release | Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results |
| 2025-12-16 | Press release | Annovis to Host Corporate Update Webinar on January 28, 2026 |
ANVS overview · ANVS earnings · ANVS financials · ANVS KPIs · ANVS ownership · ANVS peers · ANVS filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.